EUVIMEDOpdag EUVIMED
Open access

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk

Julia Karady, Thomas Mayrhofer, Borek Foldyna, Michael T Lu, Nandini Meyersohn, Udo Hoffmann, Oluwafemi Balogon, Neha Pagidipati, Svati Shah, Pamela S Douglas, Maros Ferencik, Kathleen Corey iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.18415 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Julia Karady and 11 co-authors. Institution: Cardiovascular Imaging Research Center, Harvard Medical School-Massachusetts General Hospital, Boston, Massachusetts, USA. Major MEDLINE topics: Coronary Artery Disease, Fatty Liver. Cited 1 times so far (Crossref); 37 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, NIDDK NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Hepatic steatosis (HS) and 10‐year atherosclerotic cardiovascular disease (ASCVD) risk ≥ 7.5% are associated with increased risk for cardiovascular events.

Aim

To assess underlying coronary artery disease (CAD) and major adverse cardiovascular event (MACE) among those with and without HS at different ASCVD risk.

Methods

We evaluated stable chest pain patients receiving coronary computed tomography (CT) in the PROMISE trial. HS and CAD endpoints were defined on coronary CT. MACE was defined as unstable angina, non‐fatal myocardial infarction, and all‐cause death. Multivariable Cox regression, adjusting for CAD characteristics, assessed the association of HS with MACE for ASCVD < 7.5%.

Results

One thousand two hundred and four of 3702 (32.5%) patients were at ASCVD < 7.5% and 20.3% (244/1204) of them had HS. Individuals with HS were younger (54.3 ± 5.2 vs. 55.8 ± 5.2; p < 0.001), more often males (40.2% [98/244] vs. 27.1% [260/960]; p < 0.001), had more risk factors/person (2.06 ± 0.89 vs. 1.93 ± 0.91; p = 0.047). CAD characteristics were similar between HS vs. non‐HS patients at ASCVD < 7.5% and ASCVD ≥ 7.5% (all p > 0.05). Patients with HS had greater MACE rate compared to non‐HS patients (ASCVD < 7.5%: 3.75%[9/244] vs. 1.5% [14/960]; p = 0.027 and ASCVD ≥ 7.5%: 4.7% [33/696] vs. 3.1% [56/1802]; p = 0.043). In patients without HS, MACE rate was higher in the ASCVD ≥ 7.5% vs. < 7.5% (3.1% [56/1802] vs. 1.5% [14/960]; p = 0.011). In patients with HS, MACE rates were not significantly different between ASCVD ≥ 7.5% vs. < 7.5% (4.7% [33/696] vs. 3.7% [9/244]; p = 0.484). In ASCVD < 7.5%, HS predicted MACE (aHR:2.34, 95%CI:1.01–5.43; p = 0.048), independent of CAD characteristics.

Conclusions

Individuals with HS at ASCVD < 7.5% risk had similar CAD characteristics as patients without HS at < 7.5% ASCVD risk, yet experienced comparable MACE rates as those at ASCVD ≥ 7.5%.

Subjects

MeSH terms (MEDLINE)

Coronary Artery DiseaseFatty LiverHumansMaleFemaleMiddle AgedRisk FactorsTomography, X-Ray ComputedAtherosclerosisAgedMyocardial InfarctionCardiovascular Diseases

Author keywords

cardiovascular riskcoronary CT imagingcoronary artery diseasehepatic steatosismajor adverse cardiovascular events

Authors and institutions

  • Cardiovascular Imaging Research Center, Harvard Medical School-Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany.
  • Cleerly Inc., Denver, Colorado, USA.
  • Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID profiles: Kathleen Corey

Funding

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Heart, Lung, and Blood Institute

Cite

APA

Karady, J., Mayrhofer, T., Foldyna, B., Lu, M. T., Meyersohn, N., Hoffmann, U., Balogon, O., Pagidipati, N., Shah, S., Douglas, P. S., Ferencik, M., & Corey, K. (2025). Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18415

Vancouver

Karady J, Mayrhofer T, Foldyna B, Lu MT, Meyersohn N, Hoffmann U, et al. Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18415

BibTeX
@article{Karady2025,
  author = {Karady, Julia and Mayrhofer, Thomas and Foldyna, Borek and Lu, Michael T and Meyersohn, Nandini and Hoffmann, Udo and Balogon, Oluwafemi and Pagidipati, Neha and Shah, Svati and Douglas, Pamela S and Ferencik, Maros and Corey, Kathleen},
  title = {Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.18415}
}
Start for free →